2011年11月份国外疱疹网的疫苗新消息—我们的希望 [复制链接]

真的假的？

但愿是真的，我文盲一位，就算是中文的我也未必能看明白，待海外侨胞了。

A Live-Attenuated HSV-2 ICP0− Virus Elicits 10 to 100 Times Greater Protection against Genital Herpes than a Glycoprotein D Subunit Vaccine
Research Paper published 3-11-2011


减毒活单纯疱疹病毒2型IC P0病毒引起−10到100倍更大的保护，防止生殖器疱疹一糖蛋白亚单位疫苗
研究论文发表3-11-2011

Herpes Disarmed
Dr. William Halford and collaborator are close to unveiling an innovative vaccine
"The best vaccines are live, attenuated vaccines."– Nancy Khardori, M.D.
Like a mighty warrior, the strong herpes virus easily combats and defeats the body’s immune system, which can lead to a lifetime of recurring physical infections and emotional trauma. William Halford, Ph.D., associate professor of medical microbiology, immunology and cell biology, is developing a vaccine that effectively strips the herpes virus of its strength, letting the immune system prevail.
Dr. Halford is the principal investigator on a project to develop a live, attenuated herpes vaccine. He has studied herpes simplex virus for nearly 20 years, formerly as faculty at Mon tana State University and the Tulane University School of Medicine. He joined SIU School of Medicine in 2007, and he credits state-of-the-art research facilities at SIU and recent funding from the National Institutes of Health as key factors that have accelerated his research to develop a vaccine for genital herpes.
His collaborator, David Davido, Ph.D., of the University of Kansas, is working toward a vaccine for oral and ocular herpes. These scientists are challenging not just public misconceptions of herpes, but also reticence within the scientific commu nity to consider new vaccines that contain live viruses.
“Without an effective vaccine, one in ten of our children will be infected with genital herpes by the time they are married,” Dr. Halford says.
Click here for the rest of the article

疱疹缴械
威廉博士哈尔福德和合作者接近推出一个创新的疫苗
“最好的疫苗，减毒疫苗。”–南茜khardori，医学博士
就像一个强大的战士，强大的疱疹病毒容易打击和战胜身体的免疫系统，从而导致一生的经常性的身体和感情创伤的感染。威廉哈尔福德，博士，副教授，医学微生物学，免疫学和细胞生物学，正在开发一种疫苗，有效地剥夺了疱疹病毒的力量，让免疫系统为准。
哈尔福德博士的主要研究项目制定一个生活，减毒疱疹疫苗。他研究了单纯疱疹病毒的近20年，前身为教师在蒙塔娜州立大学和杜兰大学医学院。他加入了萧医学院2007学分，和他最先进的研究设施在萧和最近的资金来自美国国立卫生研究院作为关键因素，加速了他的研究开发一种疫苗的生殖器疱疹。
他的合作者，戴维davido，博士，勘萨斯大学的工作，对口腔和眼疱疹疫苗。这些科学家正在挑战不只是公众误解的疱疹，但也保留在科学社区考虑新的疫苗含有活病毒。
“没有一个有效的疫苗，一个在我们的十个孩子将感染生殖器疱疹的时候，他们结婚了，”哈尔福德博士说。
点击这里剩下的文章

萧科学家说，疫苗
预防疱疹
由院长奥尔森
国家期刊登记
2010年1月17日出版的“上午8点8分
科学家在斯普林菲尔德南伊利诺伊大学医学院说他已经研制出一种疫苗，可以提供几乎完全防止生殖器疱疹，是世界上最常见的性传播感染。
“对我来说，这是未来的疫苗生殖器疱疹，”威廉哈尔福德说，国家期刊登记的最后一周。”令人激动的是多层次的。”
大约有1000000000人，占全球人口的六分之一-感染单纯疱疹病毒，最常见的原因，生殖器疱疹。在美国，估计有50000000人携带病毒，和高达3000000的人遭受经常性生殖器疱疹爆发为一年四次。
努力发展疫苗生殖器疱疹已经持续了几十年，数百万美元已用于疫苗研究，到目前为止，一个“非常失望，”弗莱德说wyand，发言人为北卡罗莱纳州的美国社会健康协会。
'圣杯'
一个有效的疱疹疫苗”一直是一个圣杯，”他说。”这种疫苗将成为世界各地的头条新闻。”
斯特凡妮舵手，迪凯特的医生和护士计划生育唐斯导致临床医生说伊利诺斯，疱疹疫苗”将是美好的。这是经常得到诊断疱疹。”
将寻求专利
哈尔福德，41岁，副教授，医学微生物学，免疫学和细胞生物学，说他准备发表他的研究成果在科学杂志。他还正在努力争取一个专利对他的概念，迄今已被证明不仅在实验室老鼠。
他还不愿意分享他的研究的具体细节与一般公众，但相信他的研究成果将刊登在今年晚些时候。
这将需要至少数年前将疫苗用于人体临床试验，他说。
琳达托特，小医学院的研究和国际事务学院的副院长说，哈尔福德的发现有很大的潜力。
很多人可能有利于防止收缩什么本质上是一个终身的疾病，可造成重大的问题，很多人，托特说。”他当然会有一个很新颖的方法。”
有争议的方法
哈尔福德说他的结果会引起争议，引发了科学界的辩论，并可能延缓最终批准了美国食品和药物管理局，因为他的疫苗使用的疱疹病毒活的形式。
大多数新的疫苗，现在市场上，无论是流感，乙型肝炎或人类乳头状瘤病毒（病毒），使用或一块块的蛋白质病毒-但不是一个完整的活病毒。
然而，哈尔福德指出，生活，削弱了病毒株已使用多年的儿童疫苗，以防止麻疹，腮腺炎，麻疹和小儿麻痹症。
但自20世纪70年代，当基因工程技术出现后，美国的科学家开发了广泛的哲学与创造新的活病毒疫苗是太危险的病人，哈尔福德说

Data 'clear-cut'
He said he encountered resistance from fellow scientists when trying to secure the $400,125 grant he eventually received for the final phase of his work from the National Institutes of Health.
"Their first knee-jerk reaction is that it's too dangerous, but that reaction isn't based on data. It's an impression," he said. "There's really that conceptual block to overcome."
Halford said he has changed the herpes simplex virus-2 by altering a gene known as "ICP0" so the virus no longer causes herpes symptoms.
"It absolutely loses its ability to cause disease," Halford said, adding that tests at SIU with 600 to 700 laboratory mice since July have confirmed the vaccine's effectiveness and safety.
"The data is just so clear-cut," he said.
Toth said vaccines that use live, weakened virus strains are "quite effective," though care must be used because they can cause complications for people with suppressed immune systems.
Toth said an SIU committee of scientists recently gave Halford's vaccine findings a vote of support.
"The data that he showed the committee were all very positive that this could be effective," Toth said. "There's obviously a long way to go, but so far the signs are positive that it may be safe and effective when it's translated into people."
In addition to preventing people from getting genital herpes, a successful vaccine could give more peace of mind to herpes sufferers worried about infecting their sexual partners, Toth said.
She said Halford's discovery would be good for the reputation of SIU, one of the nation's smallest medical schools. If the discovery receives FDA approval and is brought to market, it could generate annual royalties for SIU, she said.
After the costs of patent, licensing and other development costs are recovered, remaining royalties would be divided equally between Halford and the medical school, based on the school's standard policy for intellectual property, Toth said.
Halford joined SIU's faculty in 2007, but has been researching the herpes simplex virus since 1992, first focusing on HSV-1, which causes cold sores and sometimes leads to genital herpes. Laboratory technicians Brandon Rakowski and Ringo Puschel have assisted Halford in his research at SIU.
A native of New Orleans, Halford previously worked on the faculty at Montana State University in Bozeman and Tulane University School of Medicine.
Dean Olsen can be reached at 217-788-1543.
Herpes facts:
*Genital herpes in the United States increased in prevalence by 30 percent in the 1980s and 1990s, according to one study. Between one in five and one in six American adults are infected with genital herpes, but up to 90 percent of people are unaware they are infected.
*Herpes is transmitted through direct skin-to-skin contact, when a contagious area comes into contact with a tiny break in the skin or mucus-membrane tissues, primarily the mouth and the genitals.
*Most people have mild symptoms or no symptoms. Classic symptoms are sores that resemble small pimples or blisters that eventually crust over and finally scab like a small cut. The lesions may take two to four weeks to fully heal.
*While rarely leading to other health-related complications, a diagnosis of genital herpes can cause embarrassment and anxiety and lead to social isolation. Herpes outbreaks and the risk of transmission can be reduced by the frequent use of oral anti-viral medicines such as Valtrex, Famvir and Zovirax.
*Herpes can be spread when symptoms are present and not present.
*Regular condom use can decrease the rate of transmission.
*There are no documented cases of a person getting genital herpes from an inanimate object, such as a toilet seat, bathtub or towel. The herpes virus is fragile and doesn't live a long time on such surfaces.
*Blood tests and other tests are available to diagnose herpes.
*Medical costs associated with genital herpes in the United States come to somewhere between $207 million and $984 million a year, according to the most recent estimates, which are about 10 years old.
*An estimated 5,000 people die worldwide from herpes simplex virus-2 and herpes simplex virus-1. Babies, who can acquire genital herpes from their mothers in childbirth, can become extremely ill and suffer brain damage as a result of genital herpes infection.
*Herpes ulcers can enhance the transmission of human immunodeficiency virus, which causes acquired immune deficiency syndrome, or AIDS.
Sources: American Social Health Association (http://www.ashastd.org), SIU School of Medicine scientist William Halford and State Journal-Register research.
Research strengths at SIU School of Medicine
Southern Illinois University School of Medicine, which began operating in 1970 and has campuses in Springfield and Carbondale, has developed a national reputation for its research on age-related hearing loss. The school also is known for its study of innovative ways to educate medical students. SIU faculty members have received national and international attention in other research areas, as well. Here are details about some of SIU's most well-known scientists.
*SIU researcher Kathleen Campbell is developing the drug D-methionine for the prevention of hearing loss in cancer patients during chemotherapy. The drug currently is in clinical trials. Campbell's research also has contributed to the potential use of D-methionine to prevent painful inflammation in cancer patients who undergo radiation therapy.
*Donald Caspary, a neuroscientist, has worked with colleagues at SIU for more than 25 years to discover how brain chemistry changes as hearing ability declines with age. Other scientists in SIU's "auditory research group" include professor Tom Brozoski, associate professor Dr. Carol Bauer and assistant professor Jeremy Turner.
*Dr. Leonard Rybak has spent his career investigating why certain medicines that treat cancer and other ailments cause hearing loss.
*Andrzej Bartke, a physiologist at the Springfield campus since 2002, last year received an $8.6 million federal grant - the largest in the medical school's history - to expand his study of the factors affecting aging and longevity.
*Cancer is SIU's biggest growing focus of research, with a current total of $9.6 million in multi-year grant funding. SIU's top cancer researchers are Kounosuke Watabe, Yin-Yuan Mo, Dr. Deliang Cao, Daotai Nie, Sophia Ran and Dr. Laura Rogers.
*Gregory Brewer, a cell biologist, and Robert Struble, a brain-anatomy expert, are doing research into long-term treatments and cures for Alzheimer disease.
*Dr. Michael Pranzatelli, a pediatric neurologist, attracts patients from around the world who want to benefit from his research and treatments for a rare brain disease called opsoclonus-myoclonus syndrome.
Photo: William Halford, a research scientist at the Southern Illinois University School of Medicine, is closing in on a vaccine against herpes. He holds tests results indicating the effectiveness of the vaccine. Rich Saal/The State Journal-Register.

数据'明确'
他说他遭到了其他科学家试图确保400125美元的资助，他最终收到的最后阶段，他的工作由美国国家卫生研究院。
“他们的第一个本能反应是，这太危险了，但那不是基于数据的反应。这是一个印象，”他说。”真的有那块的概念来克服。”
哈尔福德说他已经改变了单纯疱疹病毒- 2的基因称为“IC P0”这样的病毒不再引起疱疹症状。
“这完全失去其能力，引起疾病，”哈尔福德说，补充说，测试在萧600700个实验室小鼠自七月以来已证实该疫苗的有效性和安全性。
“数据是如此明确，”他说。
托特说疫苗使用活，减弱病毒株是“非常有效，但必须小心使用，因为它们可能会导致并发症的人与抑制免疫系统。
托特说一个小科学家委员会最近给哈尔福德的疫苗研究结果支持的一票。
他的数据显示，该委员会都非常积极，这可能是有效的，托特说。”显然有很长的路要走，但迄今为止的迹象是积极的，它可能是安全和有效的当它进入人翻译。”
除了防止人患生殖器疱疹，一个成功的疫苗能够更安心感染疱疹患者担心他们的性伙伴，托特说。
她说，哈尔福德的发现将是很好的声誉，萧，一个国家的最小的医疗学校。如果发现收到的食品和药物管理局批准，并被带到市场，它可以产生年度版税萧，她说。
专利许可费用后，和其他开发成本回收，剩余使用费将平分哈尔福德和医疗学校，在学校对知识产权的标准政策，托特说。
哈尔福德加入了萧的教师2007名，但已经研究单纯疱疹病毒1992以来，首先侧重于单纯疱疹病毒，造成冷疮和有时导致生殖器疱疹。实验室技术员布兰登科夫斯基和林戈普希尔已协助他的研究在小哈尔福德。
土生土长的新奥尔良，哈尔福德曾任教于蒙大拿州立大学和杜兰大学医学院在波兹曼。
院长奥尔森可以达到217-788-1543。
单纯的事实：
*生殖器疱疹在美国增加患病率百分之30在80年代和90年代，根据一项研究。之间的一个五和一个在六个美国成年人感染了生殖器疱疹，但百分之90人都不知道他们被感染。
*疱疹是透过皮肤直接与皮肤接触，当接触面积接触到同一个皮肤或粘液微小的突破膜组织，主要是口腔和生殖器。
大多数人症状轻微或没有症状。典型的症状是疼痛，类似于小丘疹或水疱，最终地壳结束，最后结痂像一个小切口。病变可能需要四周的时间来完全愈合。
*虽然很少导致其他与健康有关的并发症，生殖器疱疹的诊断可能造成尴尬和焦虑，导致社会隔离。疱疹的爆发和传播的危险可减少由经常使用口服抗病毒药物，如洛韦，泛昔洛韦和舒维疗。
*疱疹可传染，症状是当前和不存在。
*经常使用避孕套可以降低传输速率。
*有些没有记载例人生殖器疱疹从一个没有生命的物体，如马桶，浴缸或毛巾。疱疹病毒是脆弱的，不住这样的表面上长的时间。
*血液检查和其他检查可诊断疱疹。
*医疗费用与生殖器疱疹在美国来介于207000000美元和984000000美元一年，根据最新的估计，大约是10岁。
*估计有5000人死于全球单纯疱疹病毒和单纯疱疹病毒1。婴儿，谁就能获得生殖器疱疹从他们的母亲在分娩时，会变得非常生病，遭受脑损伤的结果感染生殖器疱疹。
*疱疹溃疡可以提高传输的人类免疫缺陷病毒，从而导致获得性免疫缺陷综合症，艾滋病。
来源：美国社会健康协会（网址：//www.ashastd。组织），萧医学院的科学家威廉哈尔福德和国家期刊登记研究。
在萧医学院的研究实力
南伊利诺伊大学医学院，开始的1970和在斯普林菲尔德和代尔校园，已开发国家声誉的研究年龄相关性听力损失。学校也以其创新途径的研究

最后一点什么意思？疱疹病毒会变异成严重的免疫缺陷综合症还是会导致容易感染？

这是一个很不错的消息，但愿进展更快一点。感谢楼主的发现和李舜生战友的翻译，你们辛苦了！